Lonza Launches Innovaform Accelerator
Lonza inaugurated its new facility at the Colmar, France site. The new Innovaform Accelerator will serve as a Center of Excellence for developing and innovating capsule-based manufacturing and delivery solutions for oral and pulmonary administration.
Oral administration of active pharmaceutical ingredients (APIs) is preferred by patients globally, but many APIs struggle with solubility and bioavailability, limiting absorption in the gastrointestinal tract. Formulation strategies can enhance solubility and absorption, sometimes requiring capsule functionality for targeted drug release. This approach applies to small molecules, oral peptides, proteins, monoclonal antibodies, and nucleic acid-based therapeutics.
“The Innovaform Innovation and Formulation Accelerator represents a unique solution for drug developers seeking to solve complex dosage form and delivery challenges through innovation," commented Christian Seufert, President, Capsules & Health Ingredients, Lonza. "This service extension plays a critical role in our commitment to innovating together with our customers and provides our customers with the ability to accelerate their development timelines and reduce scale-up and manufacturing costs.”
Lonza’s new facility, equipped with advanced technology platforms, offers extensive expertise in formulation and encapsulation. It provides customized capsules for proof-of-concept evaluation and innovative delivery solutions using the Capsugel Enprotect technology. Lonza supports formulation development, capsule customization, encapsulation process parameter selection, compatibility studies, controlled release testing, and scale-up manufacturing assessments to meet the unique needs of each API, accelerating the market entry of innovative drug products.
